← Back to home

FDA Clears Igalmi as First Home Option for Agitation in Schizophrenia, Bipolar Disorder

Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources

Brief

The FDA approved home use of Igalmi on Nov. 16, 2026, for adults whose schizophrenia-related illness or bipolar disorder brings on…

Keep reading with NewsPlain Premium

Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.

5 confirmed facts, 1 open question and 3 sources behind this story.

About this story

We haven’t published a correction to this story.

How NewsPlain works
← Back to home